Sienna Biopharmaceuticals announced positive results from a Phase 1b trial and safety study July 24 for its SNA-120, which is being developed to treat itch associated with psoriasis. The topical product, part of the Westlake Village company’s Topical by Design platform, inhibits nerve growth factor signaling and aims to deliver high concentrations of the treatment…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
